VBI Vaccines, Inc. (NASDAQ:VBIV) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,386,251 shares, an increase of 163.4% from the June 15th total of 526,262 shares. Approximately 8.3% of the shares of the stock are short sold. Based on an average daily volume of 303,618 shares, the days-to-cover ratio is presently 4.6 days.
In other news, CEO Jeff Baxter bought 10,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average price of $3.28 per share, with a total value of $32,800.00. Following the acquisition, the chief executive officer now owns 110,255 shares in the company, valued at $361,636.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 34.10% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can increased its stake in VBI Vaccines by 8.6% in the second quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 5,000 shares in the last quarter. California State Teachers Retirement System purchased a new stake in VBI Vaccines during the second quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. purchased a new stake in VBI Vaccines during the second quarter valued at approximately $187,000. Bank of New York Mellon Corp purchased a new stake in VBI Vaccines during the second quarter valued at approximately $193,000. Finally, Teachers Advisors LLC purchased a new stake in VBI Vaccines during the second quarter valued at approximately $195,000. Hedge funds and other institutional investors own 29.49% of the company’s stock.
VBIV has been the topic of several analyst reports. ValuEngine lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Noble Financial reiterated a “buy” rating on shares of VBI Vaccines in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, TheStreet downgraded shares of VBI Vaccines from a “c-” rating to a “d+” rating in a research report on Wednesday, May 31st. Two research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.38.
Shares of VBI Vaccines (VBIV) traded down 3.80% on Tuesday, reaching $3.54. 92,129 shares of the company traded hands. The company’s market capitalization is $142.41 million. The firm’s 50 day moving average is $4.37 and its 200 day moving average is $4.61. VBI Vaccines has a one year low of $2.75 and a one year high of $6.60.
TRADEMARK VIOLATION NOTICE: This article was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://stocknewstimes.com/2017/08/15/vbi-vaccines-inc-nasdaqvbiv-short-interest-update-updated-updated-updated.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
